Die Bewertung von Orphan Drugs in der frühen Nutzenbewertung nach § 35 a SGB V im Lichte europarechtlicher Vorgaben
Focuses on the impact of the orphan designation for national HTA-procedures
Please find below some recent news of relevance for the life sciences sector as well as press releases and publications published by us.
Focuses on the impact of the orphan designation for national HTA-procedures